

Klaus Pantel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/352372/publications.pdf>

Version: 2024-02-01

314
papers

45,578
citations

2963

93
h-index

1974

206
g-index

320
all docs

320
docs citations

320
times ranked

41440
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour exosome integrins determine organotropic metastasis. <i>Nature</i> , 2015, 527, 329-335.	13.7	3,688
2	Cell-free nucleic acids as biomarkers in cancer patients. <i>Nature Reviews Cancer</i> , 2011, 11, 426-437.	12.8	2,372
3	A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 793-802.	13.9	1,274
4	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System. <i>Clinical Cancer Research</i> , 2007, 13, 920-928.	3.2	1,204
5	Dissecting the metastatic cascade. <i>Nature Reviews Cancer</i> , 2004, 4, 448-456.	12.8	1,194
6	Challenges in circulating tumour cell research. <i>Nature Reviews Cancer</i> , 2014, 14, 623-631.	12.8	1,102
7	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087
8	PGC-1 β mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. <i>Nature Cell Biology</i> , 2014, 16, 992-1003.	4.6	1,073
9	Detection, clinical relevance and specific biological properties of disseminating tumour cells. <i>Nature Reviews Cancer</i> , 2008, 8, 329-340.	12.8	1,037
10	Circulating Tumor Cells: Liquid Biopsy of Cancer. <i>Clinical Chemistry</i> , 2013, 59, 110-118.	1.5	942
11	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. <i>Nature Biotechnology</i> , 2013, 31, 539-544.	9.4	920
12	Clinical relevance of circulating cell-free microRNAs in cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 145-156.	12.5	915
13	Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer. <i>New England Journal of Medicine</i> , 2000, 342, 525-533.	13.9	881
14	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
15	Tumor metastasis: moving new biological insights into the clinic. <i>Nature Medicine</i> , 2013, 19, 1450-1464.	15.2	685
16	Liquid biopsy and minimal residual disease – latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671
17	Cancer micrometastases. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 339-351.	12.5	625
18	Circulating tumour cells in cancer patients: challenges and perspectives. <i>Trends in Molecular Medicine</i> , 2010, 16, 398-406.	3.5	616

#	ARTICLE	IF	CITATIONS
19	Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing. <i>Cancer Research</i> , 2013, 73, 2965-2975.	0.4	497
20	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	493
21	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GepearQuattro Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2634-2645.	3.2	463
22	Biology, detection, and clinical implications of circulating tumor cells. <i>EMBO Molecular Medicine</i> , 2015, 7, 1-11.	3.3	453
23	VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging $\text{CD}11\text{b}^+$ Osteoclast Progenitors. <i>Cancer Cell</i> , 2011, 20, 701-714.	7.7	445
24	Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 155-167.	12.5	426
25	Liquid Biopsy: From Discovery to Clinical Application. <i>Cancer Discovery</i> , 2021, 11, 858-873.	7.7	407
26	Liquid Biopsies, What We Do Not Know (Yet). <i>Cancer Cell</i> , 2017, 31, 172-179.	7.7	395
27	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	12.8	393
28	Data Normalization Strategies for MicroRNA Quantification. <i>Clinical Chemistry</i> , 2015, 61, 1333-1342.	1.5	384
29	Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?. <i>Cancer Research</i> , 2013, 73, 6384-6388.	0.4	376
30	Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity. <i>Clinical Cancer Research</i> , 2005, 11, 3678-3685.	3.2	372
31	Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 80-80.	0.8	367
32	Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients. <i>Cancer Cell</i> , 2013, 23, 573-581.	7.7	365
33	Clinical utility of circulating non-coding RNAs – an update. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 541-563.	12.5	353
34	Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 1188-1194.	13.9	347
35	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 403-412.	1.1	330
36	Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5701-5710.	3.2	330

#	ARTICLE	IF	CITATIONS
37	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. <i>Cancer Research</i> , 2015, 75, 892-901.	0.4	321
38	Review: Biological relevance of disseminated tumor cells in cancer patients. <i>International Journal of Cancer</i> , 2008, 123, 1991-2006.	2.3	309
39	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. <i>Genome Medicine</i> , 2013, 5, 30.	3.6	306
40	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. <i>Oncotarget</i> , 2014, 5, 9650-9663.	0.8	304
41	Frequent expression of PD-1 on circulating breast cancer cells. <i>Molecular Oncology</i> , 2015, 9, 1773-1782.	2.1	303
42	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2583-2593.	3.2	289
43	Considerations in the development of circulating tumor cell technology for clinical use. <i>Journal of Translational Medicine</i> , 2012, 10, 138.	1.8	282
44	Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells. <i>Clinical Cancer Research</i> , 2005, 11, 8006-8014.	3.2	277
45	Hematogenous dissemination of glioblastoma multiforme. <i>Science Translational Medicine</i> , 2014, 6, 247ra101.	5.8	264
46	Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone Marrow. <i>Stem Cells and Development</i> , 1994, 3, 165-173.	1.0	263
47	Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. <i>Cancer Cell</i> , 2013, 24, 542-556.	7.7	251
48	Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis. <i>Clinical Cancer Research</i> , 2011, 17, 2967-2976.	3.2	244
49	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>British Journal of Cancer</i> , 2021, 124, 345-358.	2.9	238
50	Circulating Epithelial Cells in Patients with Benign Colon Diseases. <i>Clinical Chemistry</i> , 2012, 58, 936-940.	1.5	229
51	Technologies for detection of circulating tumor cells: facts and vision. <i>Lab on A Chip</i> , 2014, 14, 57-62.	3.1	226
52	Breast cancer brain metastases: biology and new clinical perspectives. <i>Breast Cancer Research</i> , 2016, 18, 8.	2.2	226
53	Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1032-1038.	3.2	221
54	Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis. <i>Cancer Research</i> , 2013, 73, 2059-2069.	0.4	220

#	ARTICLE	IF	CITATIONS
55	Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells. <i>Developmental Cell</i> , 2018, 45, 33-52.e12.	3.1	219
56	Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer. <i>Clinical Chemistry</i> , 2013, 59, 252-260.	1.5	215
57	A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. <i>Cancer</i> , 2006, 107, 885-892.	2.0	211
58	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 16923-16935.	0.8	207
59	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	3.0	206
60	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
61	Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1840-1847.	3.0	199
62	Biologic Challenges in the Detection of Circulating Tumor Cells. <i>Cancer Research</i> , 2013, 73, 8-11.	0.4	199
63	Plasticity of disseminating cancer cells in patients with epithelial malignancies. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 673-687.	2.7	192
64	Profiling circulating tumour cells and other biomarkers of invasive cancers. <i>Nature Biomedical Engineering</i> , 2018, 2, 72-84.	11.6	187
65	Clinical applications of the CellSearch platform in cancer patients. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 102-121.	6.6	185
66	Detection and Characterization of Putative Metastatic Precursor Cells in Cancer Patients. <i>Clinical Chemistry</i> , 2007, 53, 537-539.	1.5	182
67	Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2013, 59, 1384-1392.	1.5	182
68	Liquid Biopsy: Current Status and Future Perspectives. <i>Oncology Research and Treatment</i> , 2017, 40, 404-408.	0.8	177
69	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. <i>European Urology</i> , 2012, 61, 810-817.	0.9	163
70	Prognostic impact of circulating tumor cells assessed with the CellSearch System [®] , [‡] and AdnaTest Breast [®] , [‡] in metastatic breast cancer patients: the DETECT study. <i>Breast Cancer Research</i> , 2012, 14, R118.	2.2	160
71	Detection and Monitoring of Cell-Free DNA in Blood of Patients with Colorectal Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 190-196.	1.8	158
72	Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. <i>Breast Cancer Research</i> , 2009, 11, R39.	2.2	146

#	ARTICLE	IF	CITATIONS
73	Liquid biopsies: Potential and challenges. <i>International Journal of Cancer</i> , 2021, 148, 528-545.	2.3	146
74	Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 163-174.	1.1	142
75	Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2197-2206.	3.2	135
76	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. <i>BMC Medicine</i> , 2018, 16, 179.	2.3	134
77	Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. <i>Cancer Cell</i> , 2017, 32, 731-747.e6.	7.7	133
78	Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. <i>Cancer Cell</i> , 2015, 28, 552-554.	7.7	132
79	Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2012, 18, 993-1003.	3.2	130
80	Assession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 1504-1515.	1.5	130
81	Biology and clinical relevance of EpCAM. <i>Cell Stress</i> , 2019, 3, 165-180.	1.4	127
82	Clinical relevance and biology of circulating tumor cells. <i>Breast Cancer Research</i> , 2011, 13, 228.	2.2	126
83	Exosomal microRNAs as tumor markers in epithelial ovarian cancer. <i>Molecular Oncology</i> , 2018, 12, 1935-1948.	2.1	125
84	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 503-510.	1.1	118
85	Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity. <i>Clinical Cancer Research</i> , 2014, 20, 425-433.	3.2	118
86	Liquid biopsies. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 219-232.	1.5	117
87	Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e75038.	1.1	114
88	Epithelial-mesenchymal plasticity in circulating tumor cells. <i>Journal of Molecular Medicine</i> , 2017, 95, 133-142.	1.7	113
89	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1358-1366.	2.9	110
90	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	1.7	109

#	ARTICLE	IF	CITATIONS
91	Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. <i>Clinical Chemistry</i> , 2019, 65, 87-99.	1.5	109
92	Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2013, 288, 22993-23008.	1.6	103
93	Prognostic Relevance of Viable Circulating Tumor Cells Detected by EPISPOT in Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2014, 60, 214-221.	1.5	102
94	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 380-387.	3.0	101
95	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020, 66, 149-160.	1.5	100
96	Tumor signatures in the blood. <i>Nature Biotechnology</i> , 2014, 32, 441-443.	9.4	96
97	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , 2016, 6, 39736.	1.6	96
98	Relevance of PTEN loss in brain metastasis formation in breast cancer patients. <i>Breast Cancer Research</i> , 2012, 14, R49.	2.2	93
99	Characterization of different CTC subpopulations in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 28010.	1.6	91
100	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 488-505.	12.5	91
101	Discovery of a Novel Unfolded Protein Response Phenotype of Cancer Stem/Progenitor Cells from the Bone Marrow of Breast Cancer Patients. <i>Journal of Proteome Research</i> , 2010, 9, 3158-3168.	1.8	89
102	Circulating DNA as biomarker in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 136.	2.2	89
103	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. <i>Oncotarget</i> , 2015, 6, 13387-13401.	0.8	88
104	Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion. <i>Clinical Cancer Research</i> , 2009, 15, 1566-1574.	3.2	87
105	Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. <i>International Journal of Cancer</i> , 2014, 135, 1978-1982.	2.3	87
106	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. <i>Clinical Chemistry</i> , 2016, 62, 1054-1060.	1.5	87
107	Functional Studies on Viable Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 328-334.	1.5	87
108	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	5.5	86

#	ARTICLE	IF	CITATIONS
109	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. <i>Clinical Cancer Research</i> , 2017, 23, 5384-5393.	3.2	85
110	Advances in liquid biopsy approaches for early detection and monitoring of cancer. <i>Genome Medicine</i> , 2018, 10, 21.	3.6	85
111	Blockade of Myeloid-Derived Suppressor Cell Expansion with All- <i>trans</i> Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. <i>Cancer Research</i> , 2018, 78, 3220-3232.	0.4	84
112	Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1137-1149.	2.1	84
113	Prognostic Significance of Disseminated Tumor Cells in the Bone Marrow of Prostate Cancer Patients Treated With Neoadjuvant Hormone Treatment. <i>Journal of Clinical Oncology</i> , 2008, 26, 4928-4933.	0.8	83
114	Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. <i>BoneKey Reports</i> , 2014, 3, 584.	2.7	82
115	Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer. <i>Annals of Surgery</i> , 2015, 261, 1124-1130.	2.1	82
116	Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2844-2850.	3.2	78
117	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. <i>EMBO Molecular Medicine</i> , 2020, 12, e11908.	3.3	77
118	Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. <i>Cellular Signalling</i> , 2011, 23, 1952-1960.	1.7	76
119	EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. <i>Scientific Reports</i> , 2019, 9, 7406.	1.6	73
120	Occult Tumor Cells in Bone Marrow of Patients With Locoregionally Restricted Ovarian Cancer Predict Early Distant Metastatic Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 368-375.	0.8	72
121	Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. <i>Annals of the New York Academy of Sciences</i> , 2010, 1210, 66-77.	1.8	71
122	Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. <i>Oncotarget</i> , 2016, 7, 34930-34941.	0.8	71
123	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. <i>BMC Cancer</i> , 2015, 15, 403.	1.1	70
124	Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response. <i>Cancer Research</i> , 2015, 75, 5367-5377.	0.4	70
125	Liquid biopsy: Potential and challenges. <i>Molecular Oncology</i> , 2016, 10, 371-373.	2.1	67
126	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 297-306.	1.5	67

#	ARTICLE	IF	CITATIONS
127	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. <i>Scientific Reports</i> , 2018, 8, 15931.	1.6	67
128	In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2018, 64, 536-546.	1.5	66
129	International liquid biopsy standardization alliance white paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103112.	2.0	66
130	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. <i>BMC Cancer</i> , 2014, 14, 512.	1.1	65
131	Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases. <i>American Journal of Pathology</i> , 2013, 183, 83-95.	1.9	63
132	Are circulating tumor cells predictive of overall survival?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 190-191.	12.5	61
133	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. <i>Scientific Reports</i> , 2018, 8, 12974.	1.6	59
134	Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. <i>Neuro-Oncology</i> , 2021, 23, 1087-1099.	0.6	59
135	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	0.8	58
136	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. <i>Cancer Research</i> , 2022, 82, 349-358.	0.4	57
137	Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 207.	1.3	56
138	Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. <i>Oncotarget</i> , 2017, 8, 56066-56080.	0.8	56
139	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , 2019, 21, 101.	2.2	54
140	Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. <i>PLoS ONE</i> , 2016, 11, e0155126.	1.1	54
141	Frequent detection of <i>PIK3CA</i> mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. <i>Molecular Oncology</i> , 2016, 10, 1330-1343.	2.1	53
142	Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100817.	2.7	49
143	Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. <i>PLoS Medicine</i> , 2016, 13, e1002205.	3.9	49
144	Two-Dimensional Differential Gel Electrophoresis of a Cell Line Derived from a Breast Cancer Micrometastasis Revealed a Stem/Progenitor Cell Protein Profile. <i>Journal of Proteome Research</i> , 2009, 8, 2004-2014.	1.8	48

#	ARTICLE	IF	CITATIONS
145	High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. <i>International Journal of Cancer</i> , 2012, 131, E405-15.	2.3	48
146	Characterization of single circulating tumor cells. <i>FEBS Letters</i> , 2017, 591, 2241-2250.	1.3	48
147	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid-Induced 2. <i>Cancer Discovery</i> , 2015, 5, 506-519.	7.7	45
148	Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. <i>Cancers</i> , 2018, 10, 527.	1.7	45
149	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. <i>European Journal of Cancer</i> , 2016, 63, 97-104.	1.3	44
150	Circulating Giant Tumor-Macrophage Fusion Cells Are Independent Prognosticators in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1460-1471.	0.5	44
151	Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1411-1417.	1.5	43
152	Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 46.	3.5	43
153	Disseminated breast tumour cells: biological and clinical meaning. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 129-131.	12.5	42
154	ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 396-405.	2.3	40
155	Tumour microenvironment: informing on minimal residual disease in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 325-326.	12.5	40
156	Plasma microRNA signature is associated with risk stratification in prostate cancer patients. <i>International Journal of Cancer</i> , 2017, 141, 1231-1239.	2.3	40
157	MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. <i>Cancers</i> , 2020, 12, 2009.	1.7	40
158	Disseminated Tumor Cells in Bone Marrow and the Natural Course of Resected Esophageal Cancer. <i>Annals of Surgery</i> , 2012, 255, 1105-1112.	2.1	39
159	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	3.2	38
160	Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. <i>British Journal of Cancer</i> , 2022, 127, 800-810.	2.9	38
161	AKT3 regulates ErbB2, ErbB3 and estrogen receptor β expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. <i>Cellular Signalling</i> , 2014, 26, 1021-1029.	1.7	37
162	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 3-8.	0.8	37

#	ARTICLE	IF	CITATIONS
163	ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. <i>Neuro-Oncology</i> , 2020, 22, 955-966.	0.6	36
164	Clinical relevance of cytoskeleton associated proteins for ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2195-2205.	1.2	35
165	PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. <i>Oncotarget</i> , 2017, 8, 6155-6168.	0.8	35
166	Squamous cell carcinoma of the oral cavity and circulating tumour cells. <i>World Journal of Clinical Oncology</i> , 2014, 5, 114.	0.9	35
167	Tracking tumor resistance using 'liquid biopsies'. <i>Nature Medicine</i> , 2013, 19, 676-677.	15.2	34
168	Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 205-228.	0.8	34
169	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). <i>Oncolmmunology</i> , 2020, 9, 1738798.	2.1	34
170	Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 729-738.	1.1	33
171	Heterogeneity of miR-10b expression in circulating tumor cells. <i>Scientific Reports</i> , 2015, 5, 15980.	1.6	33
172	A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 381-389.	2.3	33
173	Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. <i>Clinical Chemistry</i> , 2020, 66, 97-104.	1.5	33
174	Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer. <i>Cancers</i> , 2020, 12, 160.	1.7	32
175	Disseminated tumor cells in pancreatic cancerâ€”an independent prognosticator of disease progression and survival. <i>International Journal of Cancer</i> , 2012, 131, E475-83.	2.3	30
176	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 159-179.	1.7	30
177	Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. <i>Journal of Surgical Oncology</i> , 2006, 94, 307-315.	0.8	29
178	Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas. <i>Clinical Chemistry</i> , 2016, 62, 378-386.	1.5	29
179	Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. <i>Cancer Treatment Reviews</i> , 2022, 102, 102322.	3.4	29
180	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. <i>Oncotarget</i> , 2015, 6, 6341-6358.	0.8	28

#	ARTICLE	IF	CITATIONS
181	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	1.1	28
182	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. <i>Cancers</i> , 2020, 12, 442.	1.7	28
183	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. <i>BJU International</i> , 2017, 119, 854-861.	1.3	27
184	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	1.6	27
185	A New Era in Liquid Biopsy: From Genotype to Phenotype. <i>Clinical Chemistry</i> , 2020, 66, 89-96.	1.5	27
186	EGFR as a stable marker of prostate cancer dissemination to bones. <i>British Journal of Cancer</i> , 2020, 123, 1767-1774.	2.9	27
187	Cell lines from circulating tumor cells. <i>Oncoscience</i> , 2015, 2, 815-816.	0.9	27
188	High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. <i>Cells</i> , 2020, 9, 2129.	1.8	26
189	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6993.	1.8	26
190	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. <i>Oncotarget</i> , 2017, 8, 56398-56407.	0.8	25
191	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 431-443.	1.3	25
192	Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. <i>Clinical Chemistry</i> , 2021, 67, 631-641.	1.5	25
193	Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. <i>Pharmacogenomics</i> , 2016, 17, 183-186.	0.6	24
194	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. <i>Cancers</i> , 2019, 11, 802.	1.7	24
195	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. <i>Clinical Chemistry</i> , 2019, 65, 462-472.	1.5	24
196	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. <i>Acta Neuropathologica Communications</i> , 2020, 8, 28.	2.4	24
197	Clinical management and biology of tumor dormancy in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 78, 49-62.	4.3	24
198	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	1.3	24

#	ARTICLE	IF	CITATIONS
199	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 277-290.	1.1	23
200	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. <i>Haematologica</i> , 2018, 103, 939-948.	1.7	23
201	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , 2018, 8, 17535.	1.6	23
202	Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. <i>Cancers</i> , 2019, 11, 1685.	1.7	23
203	The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis. <i>Cancer Microenvironment</i> , 2012, 5, 59-72.	3.1	22
204	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. <i>Clinical Chemistry</i> , 2020, 66, 161-168.	1.5	21
205	Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer. <i>Annals of Surgery</i> , 2021, 273, 299-305.	2.1	21
206	HER2-targeted therapy influences CTC status in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 127-136.	1.1	21
207	Genetic traits for hematogeneous tumor cell dissemination in cancer patients. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 41-48.	2.7	20
208	Metabolic regulation of prostate cancer heterogeneity and plasticity. <i>Seminars in Cancer Biology</i> , 2022, 82, 94-119.	4.3	20
209	Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 515-515.	0.8	20
210	Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform. <i>Advanced Biology</i> , 2020, 4, 1900162.	3.0	19
211	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1055.	1.7	19
212	Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. <i>Molecular Oncology</i> , 2020, 14, 1001-1015.	2.1	19
213	Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 896.	1.1	18
214	Diverse expression patterns of the <sc>EMT</sc> suppressor grainyhead-like 2 (<sc>GRHL</sc>2) in normal and tumour tissues. <i>International Journal of Cancer</i> , 2016, 138, 949-963.	2.3	18
215	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e243-e246.	0.5	18
216	Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1505-1512.	1.5	18

#	ARTICLE	IF	CITATIONS
217	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancers</i> , 2019, 11, 933.	1.7	18
218	Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. <i>Cells</i> , 2019, 8, 1067.	1.8	18
219	Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. <i>Biochemical Pharmacology</i> , 2021, 188, 114589.	2.0	18
220	Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. <i>Oncotarget</i> , 2015, 6, 26789-26803.	0.8	18
221	RHMM splice variants confer radiosensitivity in human breast cancer cell lines. <i>Oncotarget</i> , 2016, 7, 21428-21440.	0.8	18
222	Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP transgenic mice. <i>International Journal of Cancer</i> , 2015, 136, E521-33.	2.3	17
223	Catch and Release: rare cell analysis from a functionalised medical wire. <i>Scientific Reports</i> , 2017, 7, 43424.	1.6	17
224	Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. <i>PLoS ONE</i> , 2021, 16, e0252897.	1.1	17
225	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 17307.	1.6	16
226	Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses. <i>Molecular Cancer</i> , 2022, 21, 73.	7.9	16
227	Low-grade and high-grade mammary carcinomas in WAP transgenic mice are independent entities distinguished by Met expression. <i>International Journal of Cancer</i> , 2013, 132, 1300-1310.	2.3	15
228	Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases. <i>Scientific Reports</i> , 2018, 8, 8751.	1.6	15
229	Characterization of circulating DNA in plasma of patients after allogeneic bone grafting. <i>Clinical Oral Investigations</i> , 2019, 23, 4243-4253.	1.4	15
230	Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method. <i>Cancers</i> , 2020, 12, 718.	1.7	15
231	Circulating tumour cells in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 265-266.	1.9	14
232	Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer. <i>Cancers</i> , 2021, 13, 3869.	1.7	14
233	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	0.5	14
234	ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer. <i>Translational Research</i> , 2019, 203, 49-56.	2.2	13

#	ARTICLE	IF	CITATIONS
235	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , 2020, 9, 2337.	1.8	13
236	In Vitro Modeling of Reoxygenation Effects on mRNA and Protein Levels in Hypoxic Tumor Cells upon Entry into the Bloodstream. <i>Cells</i> , 2020, 9, 1316.	1.8	13
237	Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2 ⁻ Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2 ⁻ Breast Cancer. <i>Cancers</i> , 2021, 13, 1810.	1.7	13
238	Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions. <i>British Journal of Cancer</i> , 2022, 127, 1403-1410.	2.9	13
239	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	2.3	12
240	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1395-1405.	1.5	12
241	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 571-580.	1.1	12
242	Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer. <i>International Journal of Cancer</i> , 2019, 144, 607-614.	2.3	11
243	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 155-165.	1.1	11
244	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4500.	1.7	11
245	Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer. <i>Cancer Research</i> , 2022, 82, 2213-2215.	0.4	11
246	Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells. <i>BMC Cancer</i> , 2015, 15, 178.	1.1	10
247	Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. <i>Methods in Molecular Biology</i> , 2015, 1347, 221-232.	0.4	10
248	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 279-285.	1.1	10
249	The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis. <i>Cell Death and Disease</i> , 2020, 11, 873.	2.7	10
250	Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis. <i>Cancers</i> , 2020, 12, 1166.	1.7	10
251	Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen. <i>Scientific Reports</i> , 2016, 6, 30482.	1.6	9
252	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	9

#	ARTICLE	IF	CITATIONS
253	<i>Liquid biopsy</i>: from discovery to clinical implementation. <i>Molecular Oncology</i> , 2021, 15, 1617-1621.	2.1	9
254	Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. <i>Cell Death and Disease</i> , 2021, 12, 1118.	2.7	9
255	Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients. <i>Breast Care</i> , 2009, 4, 333-338.	0.8	8
256	Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-8.	0.7	8
257	<i>BRCA1</i> promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 3615-3625.	2.1	8
258	Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer. <i>Cancer Genetics</i> , 2015, 208, 595-601.	0.2	7
259	Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 17.	2.3	7
260	Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma. <i>British Journal of Cancer</i> , 2017, 117, 612-618.	2.9	6
261	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. <i>BMC Cancer</i> , 2018, 18, 541.	1.1	6
262	Circulating Tumor Cells in Head and Neck Carcinomas. <i>Clinical Chemistry</i> , 2019, 65, 1193-1195.	1.5	6
263	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. <i>Scientific Reports</i> , 2020, 10, 21562.	1.6	6
264	The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2161.	1.8	6
265	Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 563.	1.7	6
266	The DETECT study concept: Individualized therapy of metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS634-TPS634.	0.8	6
267	A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3029-3029.	0.8	6
268	Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo. <i>Molecular Therapy</i> , 2022, 30, 1536-1552.	3.7	6
269	Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. <i>Cancers</i> , 2022, 14, 635.	1.7	6
270	A shocking protein complex. <i>Nature</i> , 2016, 538, 322-323.	13.7	5

#	ARTICLE	IF	CITATIONS
271	Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation. <i>Frontiers in Neurology</i> , 2018, 9, 391.	1.1	5
272	The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3478.	1.0	5
273	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. <i>Clinical Chemistry</i> , 2022, 68, 344-353.	1.5	5
274	Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study. <i>Molecular Oncology</i> , 2021, 15, 2877-2890.	2.1	5
275	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. <i>Carcinogenesis</i> , 2021, 42, 1475-1484.	1.3	5
276	High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients. <i>Cancers</i> , 2021, 13, 4980.	1.7	5
277	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
278	Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules. <i>JCO Precision Oncology</i> , 2022, 6, e2100378.	1.5	5
279	An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer. <i>Journal of Human Genetics</i> , 2014, 59, 661-666.	1.1	4
280	Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett's carcinoma. <i>Gut</i> , 2022, 71, 277-286.	6.1	4
281	TP53 mutations on circulating cell-free DNA. <i>EBioMedicine</i> , 2016, 10, 15-16.	2.7	3
282	Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pNO Esophageal Cancer. <i>Cancers</i> , 2020, 12, 588.	1.7	3
283	Blood tests for early detection of lung cancer: challenges and promises. <i>Lancet Respiratory Medicine</i> , 2020, 8, 654-656.	5.2	3
284	Sensitive Blood-Based Detection of Asbestos-Associated Diseases Using Cysteine-Rich Angiogenic Inducer 61 as Circulating Protein Biomarker. <i>Clinical Chemistry</i> , 2021, 67, 363-373.	1.5	3
285	Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs. <i>Clinical Chemistry</i> , 2021, 67, 1437-1439.	1.5	3
286	Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , 2021, 2195, 245-261.	0.4	3
287	Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis. <i>Blood</i> , 2018, 132, 1922-1922.	0.6	3
288	Metastatic Breast Cancer Recurrence after Bone Fractures. <i>Cancers</i> , 2022, 14, 601.	1.7	3

#	ARTICLE	IF	CITATIONS
289	Detection and Characterization of Estrogen Receptor $\hat{\pm}$ Expression of Circulating Tumor Cells as a Prognostic Marker. <i>Cancers</i> , 2022, 14, 2621.	1.7	3
290	Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis. <i>Matrix Biology</i> , 2022, 111, 76-94.	1.5	3
291	Tracing the Seeds in the Soil. <i>Clinical Chemistry</i> , 2017, 63, 1764-1765.	1.5	2
292	Molecular Diagnostics: Going from Strength to Strength. <i>Clinical Chemistry</i> , 2020, 66, 1-2.	1.5	2
293	Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC. <i>Recent Results in Cancer Research</i> , 2020, 215, 3-24.	1.8	2
294	Circulating tumor cells (CTC) and HER-2 status on CTC and primary tumor in urothelial cancer (UC) patients refractory to platinum based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4520-4520.	0.8	2
295	Liquid biopsies for surveillance and monitoring treatment response of bladder cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 379-379.	0.7	2
296	Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation. <i>Cancers</i> , 2021, 13, 5942.	1.7	2
297	Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 556.	1.7	2
298	Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. <i>Clinical Chemistry</i> , 2022, 68, 973-983.	1.5	2
299	Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer. <i>Clinical Chemistry</i> , 2017, 63, 1318-1320.	1.5	1
300	Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	1
301	HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10540-10540.	0.8	1
302	Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11042-11042.	0.8	1
303	Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11505-11505.	0.8	1
304	Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.. <i>Journal of Clinical Oncology</i> , 2018, 36, 495-495.	0.8	1
305	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	0.6	1
306	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.4	1

#	ARTICLE	IF	CITATIONS
307	Fl ¹ / ₄ ssigbiopsie: Status quo und Zukunftsperspektiven. Karger Kompass Pneumologie, 2017, 5, 206-210.	0.0	0
308	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. Blood, 2006, 108, 3947-3947.	0.6	0
309	Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia. Blood, 2011, 118, 940-940.	0.6	0
310	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	0.8	0
311	Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).. Journal of Clinical Oncology, 2013, 31, e22075-e22075.	0.8	0
312	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. Blood, 2013, 122, 1469-1469.	0.6	0
313	Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.. Journal of Clinical Oncology, 2016, 34, 11529-11529.	0.8	0
314	AXL Inhibition Represents a Novel Therapeutic Approach in Negative Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e630.	1.2	0